A primeira consulta de avaliação tem como objetivo avaliar a eficácia e tolerabilidade e equacionar terapêuticas alternativas na presença de efeitos adversos ou ineficácia (NICE, 2015). Posteriormente, efetuar revisão anual que incluí uma atualização da história médica pessoal e familiar, um exame físico, exames laboratoriais e de imagem adequados a cada situação, com discussão do estilo de vida e estratégias para prevenir e reduzir doenças cróni- cas (ANEXO II) (Baber et al., 2016).
Não há indicação para modificar o rastreio do cancro do colo do útero e do cancro da mama em mulheres sob TH (Baber et al., 2016).
Qualquer hemorragia uterina anómala na pós-menopausa deve ser investigada indepen- dentemente desta estar ou não sob TH. A ecografia endovaginal deve ser considerada o exame de primeira linha nesta investigação diagnóstica. Em caso de suspeita de patologia endometrial ou persistência de sintomas, deve ser realizado um estudo dirigido à cavidade endometrial (Baber et al., 2016).
Bibliografia
Affinito, P., Di Spiezio Sardo, A., Di Carlo, C., Sammartino, A., Tommaselli, G. A., Bifulco, G., … Nappi, C. (2003). Effects of hormone replacement therapy on ocular function in postmenopause. Menopause (New York, N.Y.), 10(5), 482–7. http://doi.org/10.1097/01.GME.0000063568.84134.35
Al-Safi, Z. A., & Santoro, N. (2014). Menopausal hormone therapy and menopausal symptoms. Fertility and Ste-
rility, 101(4), 905–915. http://doi.org/10.1016/j.fertnstert.2014.02.032
Allen, N. E., Tsilidis, K. K., Key, T. J., Dossus, L., Kaaks, R., Lund, E., … Riboli, E. (2010). Menopausal hormone the- rapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investiga- tion Into Cancer and Nutrition. American Journal of Epidemiology, 172(12), 1394–403. http://doi.org/10.1093/ aje/kwq300
Anderson, G. L., Limacher, M., Assaf, A. R., Bassford, T., Beresford, S. A. A., Black, H., … Women’s Health Ini- tiative Steering Committee. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA, 291(14), 1701–12. http://doi. org/10.1001/jama.291.14.1701
Baber, R. J., Panay, N., & Fenton, A. (2016). 2016 IMS Recommendations on women’s midlife health and meno- pause hormone therapy.
Baik, I., Becker, P. S., DeVito, W. J., Lagiou, P., Ballen, K., Quesenberry, P. J., & Hsieh, C.-C. (2004). Stem cells and prenatal origin of breast cancer. Cancer Causes & Control : CCC, 15(5), 517–30. http://doi.org/10.1023/B:- CACO.0000036450.06092.ce
Bercovici, J. P., & Darragon, T. (1980). [Administration route of natural sex steroids (estradiol, progesterone, tes- tosterone) (author’s transl)]. La Nouvelle Presse Medicale, 9(3), 179–83.
Berrino, F. (2008). Unequal risks for breast cancer associated with different hormone replacement therapies : results from the E3N cohort study, 103–111. http://doi.org/10.1007/s10549-007-9523-x
Boardman, H. M. P., Hartley, L., Eisinga, A., Main, C., Roqué i Figuls, M., Bonfill Cosp, X., … Knight, B. (2015a). Hormone therapy for preventing cardiovascular disease in post-menopausal women. The Cochrane Database of
Systematic Reviews, (3), CD002229. http://doi.org/10.1002/14651858.CD002229.pub4
Boardman, H. M. P., Hartley, L., Eisinga, A., Main, C., Roqué i Figuls, M., Bonfill Cosp, X., … Knight, B. (2015b). Hormone therapy for preventing cardiovascular disease in post-menopausal women. The Cochrane Database of
Systematic Reviews, 3(3), CD002229. http://doi.org/10.1002/14651858.CD002229.pub4
Brincat, M., Versi, E., Moniz, C. F., Magos, A., de Trafford, J., & Studd, J. W. (1987). Skin collagen changes in post- menopausal women receiving different regimens of estrogen therapy. Obstetrics and Gynecology, 70(1), 123–7. Campagnoli, C., Clavel-Chapelon, F., Kaaks, R., Peris, C., & Berrino, F. (2005). Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. The Journal of Steroid Biochemistry and Molecular
Biology, 96, 95–108. http://doi.org/10.1016/j.jsbmb.2005.02.014
Canonico, M., Oger, E., Plu-Bureau, G., Conard, J., Meyer, G., Lévesque, H., … Estrogen and Thromboembolism Risk (ESTHER) Study Group. (2007). Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation, 115(7), 840–5. http://doi.org/10.1161/CIRCULATIONAHA.106.642280
Chlebowski, R. T., Anderson, G. L., Gass, M., Lane, D. S., Aragaki, A. K., Kuller, L. H., … WHI Investigators. (2010). Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA, 304(15), 1684–92. http://doi.org/10.1001/jama.2010.1500
Cirillo, D. J., Wallace, R. B., Rodabough, R. J., Greenland, P., LaCroix, A. Z., Limacher, M. C., & Larson, J. C. (2005). Effect of estrogen therapy on gallbladder disease. JAMA, 293(3), 330–9. http://doi.org/10.1001/jama.293.3.330 Cirillo, D. J., Wallace, R. B., Wu, L., & Yood, R. A. (2006). Effect of hormone therapy on risk of hip and knee joint replacement in the Women’s Health Initiative. Arthritis and Rheumatism, 54(10), 3194–204. http://doi. org/10.1002/art.22138
Collaborative Group On Epidemiological Studies Of Ovarian Cancer, Beral, V., Gaitskell, K., Hermon, C., Moser, K., Reeves, G., & Peto, R. (2015). Menopausal hormone use and ovarian cancer risk: individual participant meta-a- nalysis of 52 epidemiological studies. Lancet (London, England), 385(9980), 1835–42. http://doi.org/10.1016/ S0140-6736(14)61687-1
Cordina-Duverger, E., Truong, T., Anger, A., Sanchez, M., Arveux, P., Kerbrat, P., & Guénel, P. (2013). Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PloS One, 8(11), e78016. http://doi.org/10.1371/journal.pone.0078016
Curb, J. D., Prentice, R. L., Bray, P. F., Langer, R. D., Van Horn, L., Barnabei, V. M., … Rosendaal, F. R. (2006). Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine,
166(7), 772–80. http://doi.org/10.1001/archinte.166.7.772
Cushman, M., Kuller, L. H., Prentice, R., Rodabough, R. J., Psaty, B. M., Stafford, R. S., … Women’s Health Initiati- ve Investigators. (2004). Estrogen plus progestin and risk of venous thrombosis. JAMA, 292(13), 1573–80. http:// doi.org/10.1001/jama.292.13.1573
Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopau- sal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. (1996). JAMA, 275(5), 370–5. ELITE, H. H. (2014). Does the trial outcome confirm or refute the timing hy- pothesis of hormone therapy? In 14th
World Congress on Meno- pause, May 1–4, 2014, Cancun, Mexico 16.
Gompel, A., & Burger, H. (2015). A Commentary on a recent update of the ovarian cancer risk attributable to menopausal hormone therapy. Climacteric: The Journal of the International Menopause Society, 18(3), 376–8. http://doi.org/10.3109/13697137.2015.1023615
Goodman, N. F., Cobin, R. H., Ginzburg, S. B., Katz, I. A., Woode, D. E., & American Association of Clinical Endo- crinologists. (2011). American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause: executive summary of recommendations. Endocrine Practice: Offi-
cial Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 17(6), 949–54.
Grady, D., Brown, J. S., Vittinghoff, E., Applegate, W., Varner, E., Snyder, T., & HERS Research Group. (2001). Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstetrics
and Gynecology, 97(1), 116–20.
Grodstein, F., Lifford, K., Resnick, N. M., & Curhan, G. C. (2004). Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstetrics and Gynecology, 103(2), 254–60. http://doi.org/10.1097/01. AOG.0000107290.33034.6f
Haarbo, J., Marslew, U., Gotfredsen, A., & Christiansen, C. (1991). Postmenopausal hormone replacement the- rapy prevents central distribution of body fat after menopause. Metabolism: Clinical and Experimental, 40(12), 1323–6.
Hammar, M. L., Lindgren, R., Berg, G. E., Möller, C. G., & Niklasson, M. K. (1996). Effects of hormonal replacement therapy on the postural balance among postmenopausal women. Obstetrics and Gynecology, 88(6), 955–60. Harden, C. L., Herzog, A. G., Nikolov, B. G., Koppel, B. S., Christos, P. J., Fowler, K., … Hauser, W. A. (2006). Hor-
mone replacement therapy in women with epilepsy: A randomized, double-blind, placebo-controlled study. Epi-
lepsia, 47(9), 1447–1451. http://doi.org/10.1111/j.1528-1167.2006.00507.x
Harman, S. M., Black, D. M., Naftolin, F., Brinton, E. A., Budoff, M. J., Cedars, M. I., … Hodis, H. N. (2014). Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Annals of
Internal Medicine, 161(4), 249–60. http://doi.org/10.7326/M14-0353
Henderson, V. W. (1997). Estrogen, cognition, and a woman’s risk of Alzheimer’s disease. The American Journal
of Medicine, 103(3A), 11S–18S.
Hendrix, S. L., Cochrane, B. B., Nygaard, I. E., Handa, V. L., Barnabei, V. M., Iglesia, C., … McNeeley, S. G. (2005). Effects of estrogen with and without progestin on urinary incontinence. JAMA, 293(8), 935–48. http://doi. org/10.1001/jama.293.8.935
Horwitz, K. B., Jackson, T. A., Bain, D. L., Richer, J. K., Takimoto, G. S., & Tung, L. (1996). Nuclear receptor coac- tivators and corepressors. Molecular Endocrinology (Baltimore, Md.), 10(10), 1167–77. http://doi.org/10.1210/ mend.10.10.9121485
Jensen, L. B., Vestergaard, P., Hermann, A. P., Gram, J., Eiken, P., Abrahamsen, B., … Mosekilde, L. (2003). Hor- mone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early post- menopausal women: a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study.
Journal of Bone and Mineral Research : The Official Journal of the American Society for Bone and Mineral Resear- ch, 18(2), 333–42. http://doi.org/10.1359/jbmr.2003.18.2.333
Kanaya, A. M., Herrington, D., Vittinghoff, E., Lin, F., Grady, D., Bittner, V., … Heart and Estrogen/progestin Re- placement Study. (2003). Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/pro- gestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine,
138(1), 1–9.
Kaunitz, A. M., & Manson, J. E. (2015). Management of Menopausal Symptoms. Obstetrics and Gynecology,
126(4), 859–76. http://doi.org/10.1097/AOG.0000000000001058
Kritz-Silverstein, D., & Barrett-Connor, E. (1996). Long-term postmenopausal hormone use, obesity, and fat dis- tribution in older women. JAMA, 275(1), 46–9.
Lobo, R. A. (2013). Where Are We 10 Years After the Women’s Health Initiative? The Journal of Clinical Endocrino-
logy & Metabolism, 98(5), 1771–1780. http://doi.org/10.1210/jc.2012-4070
Lobo, R. A., Davis, S. R., De Villiers, T. J., Gompel, A., Henderson, V. W., Hodis, H. N., … Baber, R. J. (2014). Pre- vention of diseases after menopause. Climacteric: The Journal of the International Menopause Society, 17(5), 540–556. http://doi.org/10.3109/13697137.2014.933411
Løkkegaard, E., Andreasen, A. H., Jacobsen, R. K., Nielsen, L. H., Agger, C., & Lidegaard, Ø. (2008). Hormone therapy and risk of myocardial infarction: A national register study. European Heart Journal, 29(21), 2660–2668. http://doi.org/10.1093/eurheartj/ehn408
Luine, V. N. (1985). Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and pro- jection areas of female rats. Experimental Neurology, 89(2), 484–90.
Lyytinen, H., Pukkala, E., & Ylikorkala, O. (2009). Breast cancer risk in postmenopausal women using estradiol- -progestogen therapy. Obstetrics and Gynecology, 113(1), 65–73. http://doi.org/10.1097/AOG.0b013e31818e- 8cd6
Maclennan, a H., Broadbent, J. L., Lester, S., & Moore, V. (2004). Oral oestrogen and combined oestrogen/ progestogen therapy versus placebo for hot flushes. Cochrane Database of Systematic Reviews (Online), (4), CD002978. http://doi.org/10.1002/14651858.CD002978.pub2
Maheux, R., Naud, F., Rioux, M., Grenier, R., Lemay, A., Guy, J., & Langevin, M. (1994). A randomized, double- -blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. American Journal of Obs-
tetrics and Gynecology, 170(2), 642–9.
Manson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., … Wallace, R. B. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA, 310(13), 1353–68. http://doi.org/10.1001/ jama.2013.278040
Margolis, K. L., Bonds, D. E., Rodabough, R. J., Tinker, L., Phillips, L. S., Allen, C., … Women’s Health Initiative Investiga- tors. (2004). Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial. Diabetologia, 47(7), 1175–87. http://doi.org/10.1007/s00125-004-1448-x Mauvais-Jarvis, P., Kuttenn, F., & Wright, F. (1975). [Progesterone administered by percutaneous route: an an- tiandrogen locally useful (author’s transl)]. Annales D’endocrinologie, 36(2), 55–62.
McEwen, B. S. (1999). Clinical review 108: The molecular and neuroanatomical basis for estrogen effects in the central nervous system. The Journal of Clinical Endocrinology and Metabolism, 84(6), 1790–7. http://doi. org/10.1210/jcem.84.6.5761
Mohammed, K., Dabrh, A. M. A., Benkhadra, K., Al Nofal, A., Carranza Leon, B. G., Prokop, L. J., … Murad, M. H. (2015). Oral vs transdermal estrogen therapy and vascular events: A systematic review and meta-analysis. Journal
of Clinical Endocrinology and Metabolism, 100(11), 4012–4020. http://doi.org/10.1210/jc.2015-2237
Nahoul, K., Dehennin, L., Jondet, M., & Roger, M. (1993). Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. Maturitas, 16(3), 185–202. NAMS. (2012). The 2012 Hormone Therapy Position Statement of The North American Menopause Society (NAMS). Menopause: The Journal of The North American Menopause Society, 19(3), 257–271. http://doi. org/10.1097/gme.0b013e31824b970a
Newman-Casey, P. A., Talwar, N., Nan, B., Musch, D. C., Pasquale, L. R., & Stein, J. D. (2014). The potential association between postmenopausal hormone use and primary open-angle glaucoma. JAMA Ophthalmology, 132(3), 298–303. http://doi.org/10.1001/jamaophthalmol.2013.7618
NICE. (2015). Menopause: diagnosis and management. NICE guideline NG23, (November), 1–29.
Paganini-Hill, A. (1995). The benefits of estrogen replacement therapy on oral health. The Leisure World cohort.
Archives of Internal Medicine, 155(21), 2325–9.
Philippe, E., Faguer, B., Engelman, A., Charpin, C., Loubière, R., de Mascarel, A., … Vauzelle, J. L. (1993). [The endometrium under the effects of hormone replacement therapy in menopause with percutaneous estradiol and low-dose micronized progesterone]. Pathologica, 85(1099), 475–87.
Pinkerton, J. V., Harvey, J. A., Lindsay, R., Pan, K., Chines, A. A., Mirkin, S., & Archer, D. F. (2014). Effects of baze- doxifene/conjugated estrogens on the endometrium and bone: A randomized trial. Journal of Clinical Endocrino-
logy and Metabolism, 99(2), 189–198. http://doi.org/10.1210/jc.2013-1707
Practice Bulletin No. 141. (2014). Obstetrics & Gynecology, 123(1), 202–216. http://doi.org/10.1097/01. AOG.0000441353.20693.78
Prentice, R. L., Pettinger, M., Beresford, S. A. A., Wactawski-Wende, J., Hubbell, F. A., Stefanick, M. L., & Chlebo- wski, R. T. (2009). Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women’s Health Initiative clinical trial and observational study. Cancer Epidemiology, Biomarkers & Prevention :
A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventi- ve Oncology, 18(5), 1531–7. http://doi.org/10.1158/1055-9965.EPI-08-1209
Privalsky, M. L. (2004). The role of corepressors in transcriptional regulation by nuclear hormone receptors. An-
nual Review of Physiology, 66, 315–60. http://doi.org/10.1146/annurev.physiol.66.032802.155556
Renoux, C., Dell’aniello, S., Garbe, E., & Suissa, S. (2010). Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ (Clinical Research Ed.), 340(7763), c2519. http://doi. org/10.1136/bmj.c2519
Riis, B. J., Thomsen, K., Strøm, V., & Christiansen, C. (1987). The effect of percutaneous estradiol and natural pro- gesterone on postmenopausal bone loss. American Journal of Obstetrics and Gynecology, 156(1), 61–5. Rosano, G. M. C., Vitale, C., & Fini, M. (2006). Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system? Annals of the New York Academy of Sciences, 1092, 341–8. http:// doi.org/10.1196/annals.1365.031
Rowan, J. P., Simon, J. A., Speroff, L., & Ellman, H. (2006). Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three rando- mized, controlled trials. Clinical Therapeutics, 28(6), 921–32. http://doi.org/10.1016/j.clinthera.2006.06.013 Salpeter, S. R., Cheng, J., Thabane, L., Buckley, N. S., & Salpeter, E. E. (2009). Bayesian meta-analysis of hor- mone therapy and mortality in younger postmenopausal women. The American Journal of Medicine, 122(11), 1016–1022.e1. http://doi.org/10.1016/j.amjmed.2009.05.021
Salpeter, S. R., Walsh, J. M. E., Greyber, E., & Salpeter, E. E. (2006). Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. Journal of General Internal Me-
dicine, 21(4), 363–6. http://doi.org/10.1111/j.1525-1497.2006.00389.x
Schierbeck, L. L., Rejnmark, L., Tofteng, C. L., Stilgren, L., Eiken, P., Mosekilde, L., … Jensen, J.-E. B. (2012). Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial.
BMJ (Clinical Research Ed.), 345, e6409.
Shufelt, C. L., Merz, C. N. B., Prentice, R. L., Pettinger, M. B., Rossouw, J. E., Aroda, V. R., … Manson, J. E. (2014). Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women’s Health Initiative Observational Study. Menopause (New York, N.Y.), 21(3), 260–6. http://doi. org/10.1097/GME.0b013e31829a64f9
Smith, N. L., Blondon, M., Wiggins, K. L., Harrington, L. B., van Hylckama Vlieg, A., Floyd, J. S., … Psaty, B. M. (2014). Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Internal Medicine, 174(1), 25–31. http://doi.org/10.1001/jamaintern- med.2013.11074
Smitz, J., Devroey, P., Faguer, B., Bourgain, C., Camus, M., & Van Steirteghem, A. C. (1992). A prospective rando- mized comparison of intramuscular or intravaginal natural progesterone as a luteal phase and early pregnancy supplement. Human Reproduction (Oxford, England), 7(2), 168–75.
Somboonporn, W., Panna, S., Temtanakitpaisan, T., Kaewrudee, S., & Soontrapa, S. (2011). Effects of the levo- norgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. Menopause (New York, N.Y.), 18(10), 1060–6. http://doi.org/10.1097/ gme.0b013e31821606c5
Stovall, D. W., Van Voorhis, B. J., Mattingly, K. L., Sparks, A. E., Chapler, F. K., & Syrop, C. H. (1996). The effective- ness of sublingual progesterone administration during cryopreserved embryo transfer cycles: results of a matched follow-up study. Fertility and Sterility, 65(5), 986–91.
Stuenkel, C. A. (2015). Menopausal Hormone Therapy: Current Considerations. Endocrinology and Metabolism
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V, & Santen, R. J. (2015). Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. The Journal of Cli-
nical Endocrinology & Metabolism, 100(November 2015), jc.2015-2236. http://doi.org/10.1210/jc.2015-2236
Sultana, C. J., & Walters, M. D. (1994). Estrogen and urinary incontinence in women. Maturitas, 20(2–3), 129–38. Sumino, H., Ichikawa, S., Kasama, S., Takahashi, T., Kumakura, H., Takayama, Y., … Kurabayashi, M. (2006). Dif- ferent effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflamma- tory markers in postmenopausal women. Atherosclerosis, 189(2), 436–42. http://doi.org/10.1016/j.atheroscle- rosis.2005.12.030
Sweetland, S., Beral, V., Balkwill, A., Liu, B., Benson, V. S., Canonico, M., … Million Women Study Collaborators. (2012). Venous thromboembolism risk in relation to use of different types of postmenopausal hormone thera- py in a large prospective study. Journal of Thrombosis and Haemostasis : JTH, 10(11), 2277–86. http://doi.or- g/10.1111/j.1538-7836.2012.04919.x
Takahashi, T. A., & Johnson, K. M. (2015). Menopause. Medical Clinics of North America, 99(3), 521–534. http:// doi.org/10.1016/j.mcna.2015.01.006
Torres-Arzayus, M. I., Font de Mora, J., Yuan, J., Vazquez, F., Bronson, R., Rue, M., … Brown, M. (2004). High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer
Cell, 6(3), 263–74. http://doi.org/10.1016/j.ccr.2004.06.027
Vanselow, W., Dennerstein, L., Greenwood, K. M., & de Lignieres, B. (1996). Effect of progesterone and its 5 alpha and 5 beta metabolites on symptoms of premenstrual syndrome according to route of administration. Journal of
Psychosomatic Obstetrics and Gynaecology, 17(1), 29–38.
Villiers, T. J. De, Hall, J. E., Pinkerton, J. V, Pérez, S. C., Rees, M., Yang, C., … Yang, C. (2016). Revised Global Con- sensus Statement on Menopausal Hormone Therapy. Climateric, 16, 316–333. http://doi.org/10.1080/136971 37.2016.1196047
von Eye Corleta, H., Capp, E., & Ferreira, M. B. C. (2004). Pharmacokinetics of natural progesterone vaginal su- ppository. Gynecologic and Obstetric Investigation, 58(2), 105–8. http://doi.org/10.1159/000078842 Wattanakumtornkul, S., Pinto, A. B., & Williams, D. B. (2003). Intranasal hormone replacement therapy. Meno-
pause (New York, N.Y.), 10(1), 88–98.
Worzala, K., Hiller, R., Sperduto, R. D., Mutalik, K., Murabito, J. M., Moskowitz, M., … Wilson, P. W. (2001). Post- menopausal estrogen use, type of menopause, and lens opacities: the Framingham studies. Archives of Internal
Medicine, 161(11), 1448–54.
Yeboah, J., Reboussin, D. M., Waters, D., Kowalchuk, G., & Herrington, D. M. (2007). Effects of estrogen re- placement with and without medroxyprogesterone acetate on brachial flow-mediated vasodilator responses in postmenopausal women with coronary artery disease. American Heart Journal, 153(3), 439–44. http://doi.or- g/10.1016/j.ahj.2006.11.006